KUBESPHERE
27.5.2021 09:50:06 CEST | Business Wire | Press release
KubeSphere Community announced the general availability of KubeSphere v3.1.0. KubeSphere, as an app-centric distributed operating system running on top of Kubernetes, has further expanded its portfolio to deliver more robust experiences for users across the globe, enabling DevOps teams to run Kubernetes workloads where and when they want with ease and security.
“KubeSphere has emerged as one of the most popular Kubernetes platforms ,” said Ray Zhou, Head of the KubeSphere project. “The release of KubeSphere 3.1 marks an important milestone as we further empower enterprises to gain first-mover advantages especially in edge computing.”
Taking Kubernetes From Hybrid Multi-Cloud to Edge
KubeSphere v3.1.0 provides an enabling environment for users as they can deploy production workloads not just across clouds but also at the edge . Besides, the new Metering and Billing function helps IT administrators better understand infrastructure operating costs. Existing features of multi-cluster management , multi-tenant management, observability, DevOps, application lifecycle management , and microservices governance have also been enhanced to ensure better user experiences across clusters and clouds .
Major updates include:
- Metering and billing to track infrastructure cost
- Edge node management for orchestrating apps and edge devices
- Lightweight Kubernetes multi-cloud and multi-cluster management
- Unified Kubernetes monitoring in one dashboard
- Easier Kubernetes installation
- Enhanced security with authentication and multi-tenancy
A full list of new features can be found in Release Note 3.1.0 . For a detailed introduction and interpretation, check out the latest KubeSphere 3.1.0 announcement
Commitment to Open-Source and Community
KubeSphere is making great strides on its international journey with over 100,000 downloads across 90 countries and regions to date. The KubeSphere console currently supports four official languages - English, Simplified Chinese, Traditional Chinese and Spanish.
“When you take a step back and reflect on how far KubeSphere has come, it is not surprising to find that it has become one of the most widely used container platforms not just in our country, but also around the world,” Ray added. “Our contributors from all corners of the world have shown us what open source is all about. And this is exactly what has been driving us to push the limits of what’s possible with Kubernetes.”
KubeSphere v3.1.0 remains committed to fully open source with an ever-expanding ecosystem, also helps developers to deploy code with several clicks on the friendly console, and brings integrated observability and powerful Kubernetes DevOps strategies for the Ops team.
About KubeSphere
KubeSphere is an open-source container platform based on Kubernetes. It provides full-stack IT automated operation and streamlined DevOps workflows. KubeSphere offers wizard web UI and enterprise-grade features for operation and maintenance, including multi-cloud and multi-cluster management , DevOps (CI/CD ), application lifecycle management , service mesh , multi-tenant , observability ,storage and network , and GPU support .
For more information, visit website https://kubesphere.io , GitHub https://github.com/kubesphere/kubesphere and follow @KubeSphere on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005328/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom